Oral rivaroxaban for symptomatic venous thromboembolism.
暂无分享,去创建一个
Bruce L Davidson | Giancarlo Agnelli | Sebastian Schellong | G. Raskob | M. Prins | P. Verhamme | G. Agnelli | S. Berkowitz | S. Schellong | H. Buller | H. Décousus | B. Brenner | Benjamin Brenner | Martin H Prins | Henri Bounameaux | F. Piovella | A. Lensing | Rupert Bauersachs | A. Gallus | B. Davidson | P. Wells | Peter Verhamme | Gary E Raskob | H. Bounameaux | Hervé Decousus | R. Bauersachs | A. Cohen | Frank Misselwitz | Scott D Berkowitz | Harry R Buller | Alexander Cohen | Franco Piovella | Alex S Gallus | Anthonie W Lensing | Annelise Segers | Phil Wells | F. Misselwitz | A. Segers
[1] F. Eberli,et al. Drug-eluting versus bare-metal stents in large coronary arteries. , 2010, The New England journal of medicine.
[2] Gary S Mintz,et al. In-stent restenosis in the drug-eluting stent era. , 2010, Journal of the American College of Cardiology.
[3] G. Weinstein. Extended Prophylaxis of Venous Thromboembolism with Idraparinux , 2010 .
[4] T. Andersson,et al. Drug-induced liver injury in humans: the case of ximelagatran. , 2010, Handbook of experimental pharmacology.
[5] S. Goldhaber,et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. , 2009, The New England journal of medicine.
[6] M. Gent,et al. Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement. , 2009, The Journal of bone and joint surgery. British volume.
[7] G. Raskob,et al. A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT Dose-Ranging Study. , 2008, Blood.
[8] S. Kahn,et al. Identifying unprovoked thromboembolism patients at low risk for recurrence who can discontinue anticoagulant therapy , 2008, Canadian Medical Association Journal.
[9] W. Ageno,et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. , 2008, The New England journal of medicine.
[10] G. Raskob,et al. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). , 2008, Chest.
[11] Stephen W Lagakos,et al. Statistics in medicine--reporting of subgroup analyses in clinical trials. , 2007, The New England journal of medicine.
[12] S. Ederhy. Idraparinux versus standard therapy for venous thromboembolic disease. , 2007 .
[13] Samuel Z Goldhaber,et al. Treatment of Proximal Deep-Vein Thrombosis With the Oral Direct Factor Xa Inhibitor Rivaroxaban (BAY 59-7939): The ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients With Acute Symptomatic Deep-Vein Thrombosis) Study , 2007, Circulation.
[14] R. Goldberg,et al. The worcester venous thromboembolism study , 2006, Journal of General Internal Medicine.
[15] R. Goldberg,et al. The Worcester Venous Thromboembolism study: a population-based study of the clinical epidemiology of venous thromboembolism. , 2006, Journal of general internal medicine.
[16] M. Prins,et al. Duration of treatment with vitamin K antagonists in symptomatic venous thromboembolism. , 2006, The Cochrane database of systematic reviews.
[17] G. Wensing,et al. Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59‐7939, an oral, direct factor Xa inhibitor , 2005, Clinical pharmacology and therapeutics.
[18] S. Schulman,et al. Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran. , 2003, The New England journal of medicine.
[19] E. Oger. Incidence of Venous Thromboembolism: A Community-based Study in Western France , 2000, Thrombosis and Haemostasis.
[20] Paolo Prandoni,et al. The Long-Term Clinical Course of Acute Deep Venous Thrombosis , 1996, Annals of Internal Medicine.